Express Pharma
Home  »  Latest Updates  »  Cipla partners with Eli Lilly & Company to market diabetes drug BASAGLAR

Cipla partners with Eli Lilly & Company to market diabetes drug BASAGLAR

10

BASAGLAR is a once-daily insulin glargine therapy for the treatment of patients with type 1 & 2 diabetes above two years of age

Cipla has announced its partnership with, Eli Lilly and Company (India), a 100 per cent subsidiary of Eli Lilly and Company, a global multinational pharmaceutical leader, for the marketing and distribution of Lilly’s BASAGLAR (insulin glargine injection) in India. Under this agreement, Lilly’s BASAGLAR that is manufactured by Lilly will be marketed and distributed in India by Cipla.

Umang Vohra, MD & Global CEO, Cipla said, “Diabetes continues to be a focus area for Cipla and with the launch of strong brand like BASAGLAR, Cipla will be at the forefront of providing a holistic diabetes care with the most comprehensive portfolio across orals and injectables. Cipla’s focus continues to revolve around care continuum approach for the patients it serves and create greater access to high quality treatmentand medication.”

Luca Visini, MD, Lilly India said, “Lilly is very happy to collaborate with a partner of high capabilities and with a common vision of contributing to making life better to patients across India. This strategic partnership leverages Lilly’s commitment to bring innovation to people suffering from diabetes in India and Cipla’s strong on-ground footprint across the country.”

He added, “While insulin has been a mainstay of diabetes treatment for many years, when it comes to initiating basal insulin therapy, people with diabetes still face several emotional and practical challenges. We believe that the launch of BASAGLAR, with its support for healthcare professionals and patients, is an important milestone in our journey to contribute to better diabetes care in India through our portfolio of innovative therapies and solutions”. Cipla expects to start commercialising BASAGLAR in India by end of the year 2018.

Comments are closed.